Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 3794.

https://doi.org/10.1182/blood-2023-187583

Published: 2023

Journal Articles

Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression

Minghao Dang, Hima Bansal, Maria Jose Acevedo-Calado, Li Qin, Wei Tan, Luz Yurany Moreno Moreno Rueda, Mei Huang, David Berrios Nolasco, Hans C. Lee, Krina K. Patel, Pei Lin, Sheeba K. Thomas, Donna M. Weber, Linghua Wang, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 89.

https://doi.org/10.1182/blood-2023-182902

Published: 2023

Journal Articles

Safety and Efficacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experience

Oren Pasvolsky, Michelle Hildebrandt, Naveen Subramanian, Christopher Ferreri, Hans C. Lee, Elisabet E. Manasanch, Sheeba K. Thomas, Donna M. Weber, Mahmoud Gaballa, Christen Dillard, Melody Becnel, Chitra Hosing, Pei Lin, Behrang Amini, Muzaffar H. Qazilbash, Nilesh Kalariya, Robert Z. Orlowski, Krina K. Patel

Blood (2023) 142 (Supplement 1): 4712.

https://doi.org/10.1182/blood-2023-187854

Published: 2023

Journal Articles

CD70 CAR NK Cells in the Treatment of Multiple Myeloma

Paul Lin, Francia C. Reyes Silva, Pei Lin, April L. Gilbert, Sunil Acharya, Ana K. Nunez Cortes, Pinaki Banerjee, Dexing Fang, Luciana Melo Garcia, May Daher, MD, Rafet Basar, Krina K. Patel, Hans C. Lee, Robert Z. Orlowski, Hind Rafei, David Marin, Richard E. Champlin, Elizabeth J. Shpall, Katayoun Rezvani

Blood (2023) 142 (Supplement 1): 3463.

https://doi.org/10.1182/blood-2023-190612

Published: 2023

Journal Articles

Single Cell Multi-Omic Analysis of Neoplastic Plasma Cells across the Disease Spectrum Identifies Novel Pathobiologic Mediators and Potential Therapeutic Targets in Multiple Myeloma (MM)

Luz Yurany Moreno Rueda, Keiko Akagi, Amishi U. Vora, Hans C. Lee, Krina K. Patel, Pei Lin, Bo Jiang, Yang Song, Maura L. Gillison, Sheeba K. Thomas, Donna M. Weber, Lixia Diao, Jing Wang, Elisabet E. Manasanch, David E. Symer, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 752.

https://doi.org/10.1182/blood-2023-188016

Published: 2023

Journal Articles

Duffy-Null Patients with Sickle Cell Disease Are at Risk for Low Neutrophil Counts with HU Treatment

Yan Zheng, Pei-Lin Chen, Jeffery Gossett, Guolian Kang, Clifford M Takemoto

Blood (2023) 142 (Supplement 1): 1125.

https://doi.org/10.1182/blood-2023-182459

Published: 2023

Journal Articles

A Genotype Validated Bimodal Method for the Large-Scale Identification and Phenotyping of Persons with Sickle Cell Disease Using Electronic Health Record Data

Kristin Wuichet, Clifford M Takemoto, Robert Cronin, Martha Barton, Pei-Lin Chen, Santosh L. Saraf, Mitchell J. Weiss, Michael R. DeBaun

Blood (2023) 142 (Supplement 1): 7164.

https://doi.org/10.1182/blood-2023-190521

Published: 2023

Journal Articles

Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Minghao Dang, Li Qin, Wei Tan, Liping Dong, Hans C. Lee, Krina Patel, Luz Yurany Moreno Rueda, Pei Lin, Hima Bansal, David Berrios, Sheeba K Thomas, Donna M. Weber, David E. Symer, Linghua Wang, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 7122–7124.

https://doi.org/10.1182/blood-2022-165540

Published: 2022

Journal Articles

Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Blood (2022) 140 (Supplement 1): 284–286.

https://doi.org/10.1182/blood-2022-157960

Published: 2022

Journal Articles

Acute myeloid leukemia with erythroid and megakaryocytic differentiation associated with Down syndrome

Beenu Thakral, Pei Lin

Blood (2021) 138 (23): 2446.

https://doi.org/10.1182/blood.2021013227

Published: 2021

Journal Articles

Adherence Trajectories of Extended Direct-Acting Oral Anticoagulants and Risk of Recurrent Venous Thromboembolism and Major Bleeding: A Retrospective Cohort Study

Hye-Rim Kang, Bobby L Jones, Wei-Hsuan Lo-Ciganic, Christina E DeRemer, Eric A Dietrich, Pei-Lin Huang, Martina C Murphy, Haesuk Park

Blood (2021) 138 (Supplement 1): 4059.

https://doi.org/10.1182/blood-2021-147532

Published: 2021

Journal Articles

Disease Characteristics of Multiple Myeloma Involving BRAF Mutations

Shehab Fareed Mohamed, Maliha Khan, Andres Quesada, Junsheng Ma, Pei Lin, C. Cameron Yin, Koji Sasaki, Gautam Borthakur, Naveen Pemmaraju, Qaiser Bashir, Muzaffar H. Qazilbash, Gregory P. Kaufman, Melody R. Becnel

Blood (2021) 138 (Supplement 1): 4755.

https://doi.org/10.1182/blood-2021-147400

Published: 2021

Journal Articles

Comparative Effectiveness and Safety of Extended Anticoagulant Therapy Among Medicare Beneficiaries with Venous Thromboembolism

Haesuk Park, Hye-Rim Kang, Pei-Lin Huang, Wei-Hsuan Lo-Ciganic, Eric A Dietrich, Martina C Murphy, Christina E DeRemer

Blood (2021) 138 (Supplement 1): 178.

https://doi.org/10.1182/blood-2021-153313

Published: 2021

Journal Articles

Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137555

Published: 2020

Journal Articles

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

Blood (2019) 134 (Supplement_1): 3116.

https://doi.org/10.1182/blood-2019-123205

Published: 2019

Journal Articles

C-Reactive Protein Promotes Bone Destruction in Human Myeloma By Stimulating Myeloma Cell Production of Osteolytic Cytokines Via the CD32/FcγRII-p38MAPK-Twist Axis

Jing Yang, PhD, Zhiqiang Liu, PhD, Huan Liu, PhD, Jin He, Jianling Yang, PhD, Pei Lin, MDDM,MDC, Qiang WANG, PhD, Juan Du, PhD MD, Wencai Ma, Richard E Davis, BSPharm, MS, Robert Z. Orlowski, MD PhD, Jian Hou, MD, Qing Yi, MD PhD

Blood (2017) 130 (Supplement 1): 3043.

https://doi.org/10.1182/blood.V130.Suppl_1.3043.3043

Published: 2017

Journal Articles

Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma

Elisabet E. Manasanch, MD, Rohit Mathur, PhD, Hans C. Lee, MD, Donna M. Weber, MD, Krina K. Patel, MDMSc, Sheeba K. Thomas, MD, Silvia C. Munoz, RN, Claudia Morales de Partovi, Catherine M. Claussen, MS, Pei Lin, MDDM,MDC, Behrang Amini, MD, Linghua Wang, Man Chun John MA, PhD, Yun Qing, Feng Lei, MS, Veera Baladandayuthapani, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Robert Z. Orlowski, MD PhD

Blood (2017) 130 (Supplement 1): 3089.

https://doi.org/10.1182/blood.V130.Suppl_1.3089.3089

Published: 2017

Journal Articles

MYC Copy Number Aberrancies Predict a Worse Prognosis in Patients with Diffuse Large B-Cell Lymphoma

Andres E. Quesada, MD, Parth Desai, MD, Guilin Tang, MD, Pei Lin, MD, Jason R. Westin, MD, Adam C. Seegmiller, MD PhD, C. Cameron Yin, MD PhD, Wei Wang, MD, Jie Xu, MD, Roberto N. Miranda, MD, Nishitha Reddy, MD MSCI, MBBS, L. Jeffrey Medeiros, MD, Shaoying Li, MD

Blood (2016) 128 (22): 154.

https://doi.org/10.1182/blood.V128.22.154.154

Published: 2016

Journal Articles

Thymidine Phosphorylase Exerts Complex Effects on Bone Resorption and Formation in Myeloma

Huan Liu, PhD, Zhiqiang Liu, PhD, Juan Du, MD, Jin He, M.S., Pei Lin, MD, Amini Behrang, MD, Michael W Starbuck, M.S., Nora M Novane, MD, Jatin J. Shah, MD, Richard Eric Davis, MD, Jian Hou, MD, Robert Gagel, MD, Jing Yang, PhD

Blood (2016) 128 (22): 1135.

https://doi.org/10.1182/blood.V128.22.1135.1135

Published: 2016

Journal Articles

Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results

Nina Shah, MD, Peter F Thall, PhD, Denái R. Milton, Qaiser Bashir, MD, Simrit Parmar, MD, Pei Lin, MD, Partow Kebriaei, MD, Yago Nieto, MD PhD, Uday R. Popat, MD, Chitra Hosing, MD, Amanda Cornelison, Ruby Delgado, Elizabeth J. Shpall, MD, Robert Z. Orlowski, MD PhD, Richard E. Champlin, MD, Muzaffar Qazilbash, MD

Blood (2016) 128 (22): 2269.

https://doi.org/10.1182/blood.V128.22.2269.2269

Published: 2016

NARROW

Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM)

Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression

Safety and Efficacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experience

CD70 CAR NK Cells in the Treatment of Multiple Myeloma

Single Cell Multi-Omic Analysis of Neoplastic Plasma Cells across the Disease Spectrum Identifies Novel Pathobiologic Mediators and Potential Therapeutic Targets in Multiple Myeloma (MM)

Duffy-Null Patients with Sickle Cell Disease Are at Risk for Low Neutrophil Counts with HU Treatment

A Genotype Validated Bimodal Method for the Large-Scale Identification and Phenotyping of Persons with Sickle Cell Disease Using Electronic Health Record Data

Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Acute myeloid leukemia with erythroid and megakaryocytic differentiation associated with Down syndrome

Adherence Trajectories of Extended Direct-Acting Oral Anticoagulants and Risk of Recurrent Venous Thromboembolism and Major Bleeding: A Retrospective Cohort Study

Disease Characteristics of Multiple Myeloma Involving BRAF Mutations

Comparative Effectiveness and Safety of Extended Anticoagulant Therapy Among Medicare Beneficiaries with Venous Thromboembolism

Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

C-Reactive Protein Promotes Bone Destruction in Human Myeloma By Stimulating Myeloma Cell Production of Osteolytic Cytokines Via the CD32/FcγRII-p38MAPK-Twist Axis

Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma

MYC Copy Number Aberrancies Predict a Worse Prognosis in Patients with Diffuse Large B-Cell Lymphoma

Thymidine Phosphorylase Exerts Complex Effects on Bone Resorption and Formation in Myeloma

Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only